Researches cubosomes as vesicular drug delivery system.
S. number
Name and year of researchers
Drug
Experiment
Reference
01
Hundekar et al., 2014
Diclofenac sodium
Transdermal cubosomes of Diclofenac sodium were prepared to increase the percutaneous absorption with reduced systemic side effects. It was concluded that the Diclofenac sodium cubosome gel shows enhanced drug penetration through Wistar albino rat skin in vitro and in vivo and cubosome gel containing Diclofenac sodium may offer promise as an anti-inflammatory dosage form.
Cubosomes of Amphotericin B (AmB) were prepared for enhanced oral bioavailability. AmB-loaded cubosomes were prepared by using the SolEmuls technology. The encapsulation efficiency and the results of in vitro release and stability studies in simulated gastrointestinal fluid further demonstrated that AmB was successfully encapsulated in cubosomes. Oral administration in rats did not show nephrotoxicity and its relative bioavailability was approximately 285% as compared to Fungizone.
Oral formulation of Amphotericin B (AmB) using phytantriol- (PYT-) based cubosomes was prepared. Cubosomes with reproducible, narrow particle size distribution and a mean particle size of 256.9 nm ± 4.9 nm were obtained. To overcome the poor drug solubility and increase the drug-loading rate, the encapsulation efficiency determined by HPLC assay was 87.8% ± 3.4%, and stability studies in simulated gastric fluids further confirmed that AmB was successfully encapsulated in cubosomes.
Ophthalmic cubosomes of Flurbiprofen were prepared to reduce ocular irritancy and improve bioavailability. Cubosomes were prepared using hot and high-pressure homogenization. The particle size of each cubosome formulation was about 150 nm. Histological examination revealed that neither the structure nor the integrity of the cornea was visibly affected after incubation with cubosomes bearing Flurbiprofen. The AUC FB cubosome was 486.36 ± 38.93 ng/mL·min/g, which was significantly higher than that of FB Na eye drops (). Compared with FB Na eye drops, the of FB cubosome was about 1.6-fold higher and the MRT was also significantly longer ().
Cubosome dispersions were formulated by an emulsification technique using different concentrations of a lipid phase monoolein and the nonionic surfactant, Poloxamer 407, with or without polyvinyl alcohol. The optimum formulae were incorporated in a chitosan, carbopol 940 or chitosan/carbopol mixture based hydrogels, to form cubosomal hydrogels (cubogels). For the optimal cubogel formulae, an in vivo histopathological study was conducted on rats to predict the effectiveness of the newly prepared cubogels in comparison with the commercially available cream (Dermazin). In vivo histopathological study results showed that prepared cubogels were successful in the treatment of deep second degree burn which may result in better patient compliance and excellent healing results with least side effects in comparison with the commercially available product.
Curcumin was designed into the cubosome with piperine in order to improve oral bioavailability and tissue distribution of curcumin. The characteristic of the cubosome has demonstrated that the curcumin and piperine were encapsulated in the interior of the cubosome and the crystal form was Pn3m space. The pharmacokinetic test revealed that the cubosome could improve the oral bioavailability significantly compared to the suspension of curcumin with piperine and be mainly absorbed by the spleen.
